Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel

This article was originally published in Scrip

Executive Summary

A patient access scheme has prompted NICE, the health technology appraisal institute for England and Wales, to change its mind and recommend Novartis's Tasigna (nilotinib) for chronic myeloid leukaemia (CML) patients unable to benefit from Glivec (imatinib), while Bristol-Myers Squibb is to appeal against negative recommendations on Sprycel (dasatinib). The institute also said no to Novartis' high-dose Glivec, partly because of a price increase.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel